PE firm invests in medical affairs provider: Accurate data has never been more important, says co-founder

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/pichet_w)
(Image: Getty/pichet_w)
Amulet Capital Partners – owner of SynteractHCR – is expanding its presence in the outsourced pharmaceutical services industry, with a recent investment in the medical communications provider Peloton Advantage.

Amulet Capital Partners, LP is a middle-market private equity (PE) investment firm based in Greenwich, CT.

The company, which focuses on the healthcare sector, recently completed a growth investment in Peloton Advantage, LLC, an NJ-based company that provides medical communications services to medical affairs departments at pharmaceutical, biotechnology, and medical device companies.

Outsourced pharma services is a key focus for Amulet, the company said, as it has had success in the past, including a Fund I investment in the contract research organization (CRO) SynteractHCR​.

Amulet has also led investments in the CRO PharmaNet Development Group, as well as the contract manufacturer Patheon, and pharmacy benefit manager AdvancePCS.

Over the past two years, Amulet has focused on developing “a dedicated investment thesis​” in the medical affairs space and identifying leading outsourced service providers, said Ramsey Frank, partner and co-founder of Amulet Capital Partners.

There are many macro tailwinds driving the growth within medical affairs and its evolution over time​,” he told us.

As Frank explained, medical affairs departments are now being tasked with demonstrating product value, increasing stakeholder interactions, managing data, and meeting greater transparency requirements.

The measurement, synthesis and communication of complete and accurate data generated in clinical trials has never been more important to the success of a drug​,” he added.

Pharma drug pipelines are evolving towards specialty drugs that are characterized by a larger amount of complex scientific and medical information, from which Peloton will benefit​.”

Frank said these macro tailwinds in combination with Peloton’s reputation and financial performance were key drivers for Amulet’s investment in the company.

As part of the investment, Amulet will provide resources and capital to grown Peloton’s service offerings into areas such as health economics and outcomes research (HEOR), and market access. The investment will also help the company expand its digital capabilities and geographic footprint.

Amulet’s objective is to make sure Peloton has all the tools, staff, and resources they need to succeed across the medical affairs continuum​,” said Frank.

Peloton’s management team will continue to lead the company and remain significant owners of the company.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more